Hemostemix Inc. is delighted to read out the bond letter of its plant for beginning with the first two cardiology practices via acquisition strategy, inspired by the Company’s intelligent commercialisation strategy and clinic roll-up. The intense practices of Dr Hector Rosario Figueroa and Dr Roberto Manuel Fernandez-de-Castro, the most respected and smart interventional cardiologists in the Dominican Republic, will be secured by Hemostemix for 2,000,000 shares each, entitled to TSXV approval and adjustments accordingly.
This is a different and noteworthy acquisition, as the company’s long-standing strategy till now has been to acquire beneficial and milestone-oriented accretive medical practices. In these practices, ACP-01 treatments can be counted. With the potential effort of creating an obvious, sustainable commercial stream of patient population for treatment with ACP-01, the Company’s processing capability will focus on patient treatment flow. Alongside the Hemostemix sales team will fix its concentration on elevating the practitioner-to-practitioner translation to accelerate the range of practitioners treating patients with ACP-01.
The duo of Dr Rosario Figueroa and Dr Fermandez-de-Castro have successfully treated over 200 patients with ACP-01 that making them the most experienced professional ACP-01 clinicians worldwide. Their impressive and clean track record under the safe treatment of no option, end-stage CVD patient population shows the potential of the two cardiologists to certify the feasibility, noticed efficacy, clinical relevance and safety of ACP-01 to the hospital partners, regulators, referring physicians and patients.
Their experience covers various indications such as vascular dementia, peripheral arterial disease, chronic limb-threatening Ischemia, congestive heart failure, angina and Ischemic and dilated cardiomyopathy. Their long-term patient bases, recognition and clinical expertise within the Dominican Republic’s medical population have ranked them as a perfect anchor practice, befitting Hemostemix’s first-ever international commercial and clinical footprint.
The two cardiologists will share their respective experience and expertise in cardiovascular disease treatments of dilated cardiomyopathy, Ischemic, Angina and more. They will be attentive in the clinical execution of ACP-01 therapy within the Bahamas and the Dominican Republic. They will schedule the meetings and grant the regulatory approvals from the Dominican Republic health authorities.
Alongside, these two cardiologist will sell their previous medical practice to HEM in return for the 2,000,000 common shares issuance. The unification of these practices will inaugurate the company’s clinical infrastructure, lay the ground for the future clinical trial extension, and leverage ACP-01 commercialisation.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
